Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of MBF-015 in Healthy Volunteers
NCT06049147Phase 1Completed
- Sponsor
- Medibiofarma
- Start
- Jul 2021
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MBF-015 in multiple sclerosis (MS) (11 arms), sponsored by Medibiofarma. Primary endpoint: Number of Adverse events. Started Jul 2021; status: completed.
02
Drugs
MBF-015
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT06049147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06049147.